Evidence map›Paper›PMID 37915600›Full record

ArticleiScience2023

Deciphering the mechanism of action of VP343, an antileishmanial drug candidate, in

Sameh Obeid, Eloisa Berbel-Manaia, Valérie Nicolas, Indira Dennemont, Julien Barbier, Jean-Christophe Cintrat, Daniel Gillet, Philippe M Loiseau, Sébastien Pomel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Sameh ObeidUniversité Paris-Saclay, CNRS BioCIS, 91400 Orsay, France.
Eloisa Berbel-ManaiaUniversité Paris-Saclay, CNRS BioCIS, 91400 Orsay, France.
Valérie NicolasUniversité Paris-Saclay, UMS-IPSIT, Microscopy Facility, 92019 Châtenay-Malabry, France.
Indira DennemontUniversité Paris-Saclay, CNRS BioCIS, 91400 Orsay, France.
Julien BarbierUniversité Paris-Saclay, UMS-IPSIT, Microscopy Facility, 92019 Châtenay-Malabry, France.
Jean-Christophe CintratUniversité Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
Daniel GilletUniversité Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.
Philippe M LoiseauUniversité Paris-Saclay, CNRS BioCIS, 91400 Orsay, France.
Sébastien PomelUniversité Paris-Saclay, CNRS BioCIS, 91400 Orsay, France.
Université Paris-Saclay · FRCentre National de la Recherche Scientifique · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInstitut Galien Paris-Saclay · FRLaboratoire des Biomolécules · FRTechnologies pour la Santé · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antileishmanial chemotherapy is currently limited due to severe toxic side effects and drug resistance. Hence, new antileishmanial compounds based on alternative approaches, mainly to avoid the emergence of drug resistance, are needed. The present work aims to decipher the mechanism of action of an antileishmanial drug candidate, named VP343, inhibiting intracellular

Indexed as

Cell biologyDrugsParasitology

Identifiers

PMID37915600
PMCPMC10616420
OpenAlexW4387358564

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.